Mankind Pharma Inks Deal for Two Insulin Analogues
The Story: Mankind Pharma has entered an exclusive agreement with Chongqing Chenan to commercialize Insulin Degludec and Insulin Degludec + Aspart in India.
The Take: The deal strengthens Mankind’s diabetes portfolio and expands its presence in the injectable insulin market through a China-focused in-licensing strategy.
Strides Pharma Receives USFDA Clearance
The Story: Strides Pharma has received the USFDA’s EIR for its Bengaluru facility, closing the May 2026 inspection after addressing five observations.
The Take: The regulatory closure reduces uncertainty around the facility and supports continued global supply and future product opportunities.
Hearzap Acquires Amplifon India’s Hearing Business
The Story: Hearzap has completed the acquisition of Amplifon India’s hearing healthcare business, adding around 240 hearing care points and expanding its network to 420 centres.
The Take: The deal strengthens Hearzap’s position in India’s organised hearing care market and moves it closer to its 500-centre target by 2027.
Piramal Pharma Acquires Yapan Bio Stake
The Story: Piramal Pharma has acquired an additional 40.67% stake in Yapan Bio for ₹76 crore, taking its ownership to 74%.
The Take: The deal strengthens Piramal’s large-molecule and ADC CDMO capabilities, expanding its end-to-end biologics development and manufacturing offering.
Optimus Pharma Gets DCGI Nod for Tapinarof
The Story: Optimus Pharma has become the first Indian company to receive DCGI approval to manufacture and market Tapinarof Cream 1% for plaque psoriasis.
The Take: The approval gives Optimus an early-mover advantage in India’s psoriasis market with a non-steroidal treatment option.
